At present, there are many drugs used clinically for anti-rejection in liver transplantation, mainly including glucocorticoids, anti-proliferative drugs, T-cell-mediated immunosuppressants, etc. Glucocorticoids mainly include sodium hydrocortisone succinate, methylprednisolone sodium succinate, prednisone, prednisolone, and dexamethasone. Hormones can be used not only alone, but also in combination with anti-proliferative drugs or calcium phosphatase inhibitors, mainly for basic treatment, and are also the first choice for acute rejection. The main anti-proliferative drug is mortification, which can relatively specifically inhibit lymphocyte proliferation and antibody formation, and is mainly used for clinical maintenance treatment. The current principles for the use of anti-rejection drugs in liver transplantation are to combine drugs, reduce the dose and toxic effects of single drugs, and increase the synergistic effect. A common triple drug regimen uses a calcium phosphatase inhibitor in combination with glucocorticoids and antiproliferative drugs.